MoonLake Immunotherapeutics (MLTX) Stock Price & Analysis

MoonLake Immunotherapeutics (MLTX) closed at USD 11.85 on Friday, October 23, 2026, down 3.97% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 12.34; the Oct 23, 2026 session ranged USD 11.48–12.28 on volume of 1,931,208 shares. Market capitalization is $1.01B, with a 52-week range of USD 9.36–23.29 (NCM). Source: Nexqual, retrieved October 24, 2026 at 02:20 UTC.

Also available as compact Markdown for AI agents: nexqual.com/MLTX.md

Key facts (MLTX)

• Insider open-market sales, last ~7 months: 13 Form 4 filings, $14.1M; 1 not under a Rule 10b5-1 plan ($2.8M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.33 on a 1–5 scale) (15 analysts), mean target USD 28.54 (range 6–50).
• Total return with dividends: 1Y +24.5% vs S&P 500 +13.4%; 5Y +18.5% vs S&P 500 +76.9%.
• Next earnings: 2026-11-05, EPS estimate USD -0.78, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MLTX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (MLTX)

P/B 2.4x · FCF yield -22.33% · Earnings yield -26.14% · Net cash $437M · EV $571M

Insider sales (SEC Form 4, open-market, last ~7 months) (MLTX)

12 of 13 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (MLTX)

Consensus Buy (mean 2.33 on a 1–5 scale), 15 analysts; mean target USD 28.54 (low 6, high 50).

Rating changes, last 120 days:

Total return (dividends reinvested) (MLTX)

MLTX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 25, 2026.

MLTX company outlook (results filed Aug 10, 2026)

• “The Company expects to have sufficient capital to fund its operating expenses and capital expenditure requirements to mid-2028.”
• “In VELA-2, intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the Week 16 primary endpoint using the composite strategy (HiSCR75, delta to placebo of 9%, p=0.053).”
• “Real-world data in the United States indicate that at least 2 million unique patients have been diagnosed with and treated for HS between 2016 and 2023 alone, highlighting a significant unmet need and impact on healthcare systems, and a market opportunity projected to reach $15 billion by 2035.”
• “IZAR-1 is expected to enroll biologic-naïve patients and include an evaluation of radiographic progression, while IZAR-2 is expected to enroll patients with an inadequate response to tumor necrosis factor-α inhibitors (TNF-IR) – reflecting patients commonly seen in clinical practice – and is the first PsA trial to include a risankizumab active reference arm.”

Quoted word-for-word from the SEC 8-K results press release.

MLTX analyst estimates and revisions

MLTX options: expected move

Options price a move of about ±19.4% (±$2.33) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±3.1% on average.

30-day implied volatility 104.6% vs 67% realized over the last 30 trading days. Put/call ratio (volume) 0.26. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 24, 2026 at 02:20 UTC)

Technical Analysis (MLTX)

Nexqual's technical model rates MLTX "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 24, 2026 at 02:20 UTC.

Analyst Ratings (MLTX)

Wall Street analysts rate MLTX "Buy" based on 15 analysts, with a mean price target of USD 28.54 (range USD 6–50), per Nexqual as of October 24, 2026 at 02:20 UTC.

Earnings (MLTX)

Recent Earnings History

Source: Nexqual, October 24, 2026 at 02:20 UTC.

Financials & Fundamentals (MLTX)

Source: Nexqual, October 24, 2026 at 02:20 UTC.

Financial Health Score (MLTX)

Nexqual rates MoonLake Immunotherapeutics's overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 02:20 UTC.

Ownership (MLTX)

Source: Nexqual, October 24, 2026 at 02:20 UTC.

Leadership (MLTX)

MoonLake Immunotherapeutics is led by Jorge Santos da Silva, Co-Founder, Interim Chair of the Board & CEO, per Nexqual as of October 24, 2026 at 02:20 UTC.

Major Backers & Investors (MLTX)

Notable institutional backers of MoonLake Immunotherapeutics include BVF Inc., Deep Track Capital, Lp, T. Rowe Price, according to Nexqual as of October 24, 2026 at 02:20 UTC.

Active Investors

Source: Nexqual, October 24, 2026 at 02:20 UTC.

From MoonLake Immunotherapeutics's Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• As of December 31, 2025, we have the exclusive license to a patent family directed to Il-17 Nanobodies, including SLK, and methods of making and using the same derived from International Patent Application PCT/EP2012/058313, published as WO 2012/156219, entitled "Amino Acid Sequences Directed Against IL-17A, IL-17F and/or IL17-A/F and Polypeptides Comprising the Same".
• In November 2025, we were granted a Type B meeting with the FDA to discuss adequacy of the current clinical evidence package of SLK in HS to support a Biologics License Application ("BLA") and in January 2026, we announced positive feedback from this interaction, confirming that we may establish substantial evidence of effectiveness ("SEE") without additional clinical trials in HS.
• The trial also evaluated a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System ("IHS4"), the proportion of patients achieving a Dermatology Life Quality Index ("DLQI") total score of ≤5, and the proportion of patients achieving at least 30% reduction from baseline in Numerical Rating Scale in the Patient's Global Assessment of Skin Pain ("PGA Skin Pain").
• The agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.

Partnerships

• On April 29, 2021, we entered into a license agreement with MHKDG (the "License Agreement").
• Effective July 1, 2021, we entered into a contract manufacturing agreement with Richter Biologics with respect to the manufacture of SLK.

Legal & Regulatory Risks (Item 1A, quoted)

• The regulatory approval processes of the FDA, EMA, and other comparable foreign regulatory authorities are complex, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for SLK, we may not be able to commercialize, or may be delayed in commercializing, SLK, and our ability to generate revenue will be materially impaired.
• We have never successfully completed the regulatory approval process for any of our product candidates and we may be unable to do so for any product candidates we acquire or develop.
• The results of preclinical testing and early clinical trials may not be predictive of the success of our later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA, or other comparable foreign regulatory authorities.
• Risks Related to Regulatory Process and Other Legal Compliance Matters

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 02:20 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt